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ABSTRACT
MicroRNAs (miRNAs) are endogenous 22 nt non-coding RNAs that target mRNAs 
for cleavage or translational repression. Numerous miRNAs regulate programmed cell 
death including apoptosis, autophagy and necroptosis. We summarize how miRNAs 
regulate apoptotic, autophagic and necroptotic pathways and cancer progression. We 
also discuss how miRNAs link different types of cell death.
INTRODUCTION
Programmed cell death (PCD) is defined as 
regulated cell death executed by an intracellular program. 
Apoptosis was traditionally thought to be the only form 
of programmed cell death. However, in the last decade, 
programmed cell death has expanded to include autophagy 
and necroptosis (programmed necrosis). These modes 
of programmed cell death, especially apoptosis and 
necroptosis, serve as natural barriers that restrict malignant 
cells from survival and dissemination.
A breakthrough in cell and molecular biology in the 
last decade is the discovery of a new class of endogenous, 
noncoding small RNAs (microRNAs/miRNAs). The function 
of these miRNAs is to control gene expression by acting on 
their target mRNAs, leading to either mRNA degradation 
or translational repression. Numerous miRNAs have been 
reported to perform specific functions in the regulation of 
tumor progression and multiple drug resistance [1–8].
In this review, we summarize how miRNAs 
regulate apoptosis, autophagy, and necroptosis and focus 
on the impact of these regulatory activities on cancer 
progression. We also discuss how miRNAs bridge the 
crosstalk between different types of cell death. At the 
end of this review, we highlight the future challenges and 
propose possible research directions in this field based on 
our current understanding.
An introduction to microRNAs
MiRNAs are highly conserved, small noncoding 
RNA molecules that function to regulate a wide 
variety of cellular processes by interfering with protein 
expression or mRNA degradation [9]. In mammals, 
miRNAs are estimated to regulate approximately 50% 
of all protein-coding genes and play important roles in 
all types of biological events, including cell proliferation 
and differentiation, cell fate determination, signal 
transduction, organ development, host-viral interactions, 
tumorigenesis and progression [9, 10]. miRNAs act as 
guides for the miRNA-RNA-induced silencing complex 
(miRNA-RISC) to specifically regulate their target 
mRNAs. With few exceptions, the miRNA-binding sites 
normally lie in the 3’-untranslated regions (3’-UTRs) of 
mRNAs. The binding of miRNAs to mRNAs involves the 
Watson-Crick base pairing of miRNA nucleotides 2–8, 
representing the seed region [11]. The degree of miRNA-
mRNA complementarity is considered to be a key factor 
affecting the regulatory mechanism of miRNA. Perfect 
complementarity triggers the Ago-catalyzed cleavage of the 
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mRNA strand, whereas central region mismatches exclude 
this cleavage but inhibit mRNA translation [11, 12].
MicroRNAs and apoptosis
Apoptotic pathways
There are two basic apoptotic signaling pathways: 
the extrinsic and intrinsic apoptotic pathways [13]. 
The intrinsic (or mitochondrial) apoptotic pathway is 
triggered by a variety of intracellular stimuli, including 
DNA damage, cytotoxic drug treatment, growth factor 
deprivation, and/or oxidative stress. This pathway relies 
on the formation of a complex termed the apoptosome, 
which is composed of procaspase-9, apoptotic protease 
activating factor 1 (Apaf-1), and cytochrome c. A series of 
Bcl-2 family members including Bax, Bak, Bcl-2, Bcl-xL, 
Mcl-1, Bid, and Bim control the release of cytochrome c 
by regulating mitochondrial membrane permeabilization. 
Notably, Bax and Bak homo-oligomerize on the surface 
of mitochondria to promote pore formation in the outer 
mitochondrial membrane. Pro-apoptotic factors such as 
cytochrome c leak out of mitochondria via these pores 
and play important roles in the induction of apoptosis. The 
extrinsic pathway of apoptosis is initiated by the binding 
of death ligands [e.g., Fas ligand (FasL), TNF-related 
apoptosis-inducing ligand (TRAIL), TNF-α, and TNF-like 
weak inducer of apoptosis (TWEAK)] to death receptors 
in the TNF receptor (TNFR) superfamily [e.g., Fas, death 
receptor (DR)4/5, TNFR, and DR3]. This interaction 
is followed by the assembly of the death-inducing 
signaling complex (DISC), which consists of the Fas-
associated death domain-containing protein (FADD) and 
procaspase-8/10. DISC then either activates downstream 
effector caspases (caspase-3, 6 and 7) to directly induce 
cell demise or cleaves the Bcl-2 family member Bid to 
form tBid, thereby triggering the mitochondria-mediated 
intrinsic apoptotic pathway [13]. In addition to these two 
well-known apoptotic pathways, chronic endoplasmic 
reticulum (ER) stress also triggers apoptosis via the 
activity of inositol-requiring protein-1 (IRE1) and C/
EBP-homologous protein (CHOP). These alternative 
signaling cascades may interact with the intrinsic or 
extrinsic apoptotic pathway at some points [14]. The major 
apoptotic processes are depicted in Figure 1.
Numerous factors such as Smads, mammary serine 
protease inhibitor (Maspin), death-associated protein 
kinase (DAPK), p53, cellular inhibitor of apoptosis 
proteins (cIAPs), and NF-κB have been reported to be 
involved in the regulation of apoptotic pathways [15]. 
Interestingly, these factors often act at more than one node 
in either the intrinsic or extrinsic apoptotic pathway. p53, 
a classic pleiotropic regulator of cell fate in response to 
DNA damage, trans-activates several pro-apoptotic Bcl-2 
family members (Bax, Bid, PUMA, and NOXA), Apaf-
1, caspase-6 and -8, the two central death receptors Fas 
and DR5, and the death ligand TRAIL but trans-represses 
anti-apoptotic factors such as Bcl-2 and survivin. In 
addition to transcriptional regulation, p53 directly 
modulates mitochondrial function by promoting the 
oligomerization of Bax and Bak and by interacting with 
Bcl-2, Bcl-xL, and Mcl-1 [16, 17].
miRNAs that regulate the intrinsic apoptosis pathway
Many miRNAs have been shown to be involved in 
regulating the intrinsic apoptotic pathway and in inhibiting 
tumor growth. miR-365, which is highly expressed in 
invasive ductal adenocarcinoma, directly targets the 
adaptor protein Src homology 2 domain-containing 1 
(SHC1) and the pro-apoptotic protein Bax, and these 
interactions are associated with gemcitabine resistance 
in pancreatic cancer cells [18]. miR-125b conferred the 
resistance of breast cancer cells to paclitaxel via the 
suppression of pro-apoptotic Bak expression [19]. miR-
491 directly targets Bcl-xL and significantly decreases 
the viability of human DLD-1 colorectal cancer cells 
by inducing apoptosis. Treatment with miR-491 also 
suppresses DLD-1 cell-derived tumor growth in nude 
mice in vivo [20]. miR-133a was shown to be down-
regulated in osteosarcoma cell lines and in primary 
human osteosarcoma tissues, and this down-regulation 
strongly correlated with tumor progression and prognosis. 
The restoration of miR-133a inhibited cell proliferation, 
induced apoptosis, and suppressed tumorigenicity in 
osteosarcoma cell lines. The tumor-suppressive activity 
of miR-133a is likely due to the targeted suppression 
of Bcl-xL and Mcl-1 expression [21]. miR-608 was also 
reported to target Bcl-xL to regulate chordoma malignancy 
[22]. miR-15a and miR-16–1 were shown to be frequently 
deleted or down-regulated in a majority of chronic 
lymphocytic leukemia (CLL) cases, and their expression 
inversely correlated with Bcl-2 expression. A further study 
showed that these two miRNAs negatively regulate Bcl-2 
at the posttranscriptional level via direct inhibition [23] 
and induce apoptosis. miR-204 is another suppressor 
of Bcl-2 expression. The down-regulation of miR-204 
correlated with increased Bcl-2 protein staining in human 
gastric cancer (GC) specimens. The ectopic expression 
of miR-204 inhibited colony formation, cell migration 
and tumor engraftment by GC cells and increased the 
responsiveness of GC cells to 5-fluorouracil or oxaliplatin 
treatment [24]. miR-148a and miR-24–2c also directly 
suppress Bcl-2 expression [25, 26]. miR-23a/b and miR-
27a/b act as endogenous inhibitors of Apaf-1 expression 
and control the sensitivity of neurons to apoptosis [27]. 
miR-133 and miR-24a were observed to directly repress 
caspase-9 to regulate cell fate (Figure 1) [28, 29].
miRNAs that regulate the extrinsic apoptotic pathway
miRNAs are also involved in regulating the 
extrinsic apoptotic pathway. FasL was reported to be 
a direct target of miR-21, and the ectopic expression of 
miR-21 protected cancer cells from gemcitabine-induced 
apoptosis [30]. miR-590, which is highly expressed in the 
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human acute myeloid leukemia (AML) cell line AML-
193, inhibited FasL expression in AML and promoted cell 
survival [31]. miR-20a down-regulated Fas expression in 
osteosarcoma cells, thus enhancing the metastatic capacity 
of osteosarcoma cells by promoting cell survival in the 
FasL-positive lung microenvironment [32]. miR-146a and 
miR-196b are also potent suppressors of Fas expression 
[33, 34]. The ectopic expression of miR-196b led to more 
aggressive leukemic phenotypes and caused much more 
rapid leukemogenesis upon secondary transplantation. 
However, the overexpression of Fas reversed these miR-
196b-mediated phenotypes [34].
miR-25 expression is elevated in malignant 
cholangiocarcinoma cells. It was demonstrated that miR-25 
targets the TRAIL receptor DR4 and promotes the evasion 
of TRAIL-induced apoptosis in cholangiocarcinoma [35]. 
miR-K10a was reported to prevent TWEAK-induced 
apoptosis by targeting the TWEAK receptor (TWEAKR) 
[36]. In contrast to other death ligands, TNF-α can 
trigger either apoptosis or cell survival depending on its 
downstream signaling complexes. miR-187, miR-181c, 
and miR-34a were shown to directly target TNF-α mRNA 
to regulate apoptosis or inflammation [37–39]. FADD 
can be transcriptionally regulated by miR-155 [40] or 
Figure 1: miRNAs regulate the major apoptosis pathways. The orange region represents the extrinsic apoptotic pathway; the 
yellow region represents the intrinsic apoptotic pathway; the blue region represents ER stress-induced apoptosis; the purple region represents 
common members of different apoptotic pathways; the green region represents critical regulators controlling apoptosis. Major miRNAs that 
regulate apoptosis effectors are shown in the diagram in dark blue. FasL, Fas ligand; TRAIL, TNF-related apoptosis-inducing ligand; DR4, 
death receptor 4; FADD, Fas-associated death domain protein; c-FLIP, cellular FLICE-like inhibitory protein; CHOP, C/EBP-homologous 
protein; IRE1, inositol-requiring protein-1; XIAP, X-linked inhibitor of apoptosis; Maspin, mammary serine protease inhibitor; DAPK, 
death-associated protein kinase; cIAP1/2, cellular inhibitor of apoptosis 1/2; Smac, second mitochondria-derived activator of caspases, also 
referred to as DIABLO. See the text for details.
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miR-128a [41]. Increased miR-128a levels were frequently 
observed in acute lymphoblastic leukemia (ALL). The 
ectopic expression of miR-128a conferred Fas resistance to 
Jurkat cells by directly targeting FADD, but antagonizing 
miR-128a function sensitized cells to Fas-mediated 
apoptosis [41]. Because caspase-8 is a key checkpoint 
protein that regulates the transition between apoptosis 
and necroptosis, the suppression of caspase-8 expression 
by miR-874 promotes the induction of necroptosis [42]. 
miR-186* was reported to regulate caspase-10, which is 
highly homologous to casapse-8 [43]. Cellular FLICE-like 
inhibitory protein long form (c-FLIPL), which is highly 
homologous to procaspase-8 but displays no protease 
activity, is recruited to DISC and prevents the activation of 
procaspase-8. Dysregulation of c-FLIPL has been shown to 
be associated with the malignancy of most human cancers. 
miR-512–3p negatively regulates c-FLIP expression 
by acting on a conserved miRNA-binding site in the 3′-
UTR of c-FLIP and enhances Taxol-induced apoptosis in 
HepG2 hepatocellular carcinoma cells (Figure 1) [44].
miRNAs that regulate the ER stress-induced apoptotic 
pathway
miR-211 was shown to be induced by ER stress and 
to facilitate the histone H3K27 methylation of the CHOP 
(a key effector that responds to ER-stress) promoter, 
leading to the suppression of CHOP expression and to cell 
survival [45]. Interestingly, CHOP up-regulates miR-708, 
which functions in relieving ER stress and maintaining the 
homeostasis of ER function (Figure 1) [46].
miRNAs that regulate the executioner caspases
Caspase-3, -7, and -6 are effector caspases that act 
on different apoptotic pathways to execute cell death. miR-
let-7a, plays an important role in the modulation of drug-
induced apoptosis by targeting caspase-3 in human cancer 
cells [47]. miR-378 and miR-155 were also reported to 
target caspase-3 mRNA to attenuate apoptosis [40, 48]. 
miR-106b, which is up-regulated in both human primary 
prostate tumors and distant metastases, was shown to 
target caspase-7 and to be associated with the recurrence 
of prostate cancer (Figure 1) [49].
miRNAs that control the key regulators of apoptosis
DAPK is a classic pro-apoptotic factor and meta-
stasis suppressor. miR-103 and miR-107 promote 
colorectal cancer metastasis by targeting DAPK and 
Krüppel-like factor 4 (KLF4) [50]. Smad proteins are 
critical mediators of TGF-β-induced pro-apoptotic 
signaling. It was reported that miR-21 binds to the 3′-
UTR of Smad7 mRNA to inhibit its translation [51]. 
miR-224 accelerates hepatoma cell migration and tumor 
formation by silencing Smad4 [52]. miR-125b was 
reported to act as a direct negative regulator of p53 and 
p53-induced apoptosis during development and stress 
responses [53]. miR-380–5p inhibits p53 expression 
by binding to a conserved sequence in the p53 3′-UTR. 
The suppression of endogenous miR-380–5p expression 
in embryonic stem or neuroblastoma cells increases the 
p53 level, causing extensive apoptotic cell death. The 
in vivo delivery of a miR-380–5p antagonist diminished 
the tumor size in a mouse neuroblastoma model [54]. 
Moreover, miR-214, miR-30a/b/d, miR-504, and miR-
138 act as direct negative regulators of human p53 [55–
58]. Notably, p53 is also a regulator of several miRNAs, 
constituting a complex circuit between miRNAs and p53 
that is involved in the regulation of various physiological 
and pathological processes [59–61]. Mutant p53 proteins 
can also transcriptionally regulate the expression of some 
miRNAs and can exert oncogenic activities [62].
X-linked inhibitor of apoptosis (XIAP) is a 
critical apoptosis inhibitor that targets multiple caspase 
activations. Both miR-23a and miR-24 directly target the 
3′-UTR of XIAP mRNA [63]. miR-24 overexpression 
abolished apoptosis resistance in cancer cells via the 
suppression of XIAP expression [64]. Survivin, a potent 
anti-apoptosis regulator, was reported to serve as a direct 
target of miR-218 and miR-203 [65, 66]. NF-κB is a 
pivotal protein complex that antagonizes apoptosis and 
facilitates tumor progression. A series of miRNAs have 
been demonstrated to be involved in the direct or indirect 
suppression of NF-κB activity. A few miR-520/373 
family members (e.g., miR-372, -373, -520c, and -520e) 
inhibited NF-κB signaling and abrogated the secretion of 
the pro-inflammatory cytokines IL-6 and IL-8 by directly 
targeting RelA [67]. miR-30e* enhanced human glioma 
cell invasiveness in an orthotopic xenotransplantation 
model by disrupting the inhibitor of NF-κB alpha (IκBα) 
[68]. Moreover, miR-195 is involved in the regulation 
of NF-κB activity by targeting two critical activators of 
NF-κB, IκB kinase α (IKKα) and TAB3 (Figure 1) [69].
MicroRNAs and autophagy
Autophagy and its regulation
Autophagy is a regulated cellular program that 
involves the following events: autophagy induction, 
vesicle nucleation (or formation of a phagophore), vesicle 
elongation and autophagosome formation, autophagosome 
retrieval (an intermediate recycling step for the recruitment 
of lipids and certain regulatory proteins to the growing 
phagophore), fusion of the autophagosome to a lysosome/
endosome and autolysosome formation, and autolysosome 
cargo degradation [70]. Several molecular complexes 
or components are very important for the process of 
autophagosome formation. These components are: (a) 
the UNC-51-like kinase (ULK) complex; (b) the class III 
phosphatidylinositol-3 kinase (PI3K) complex; (c) two 
ubiquitin-like protein conjugation systems, the ATG12 
conjugation system and the microtubule-associated 
protein 1 light chain 3 (LC3) conjugation system; and (d) 
two transmembrane proteins, autophagy-related gene 9 
(ATG9) and vacuole membrane protein 1 (VMP1) [71]. 
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Additionally, p62 is a cargo receptor for ubiquitinated 
proteins that plays a role in selectively delivering these 
proteins to the autophagosome [72].
The ULK complex, which is composed of ULK1, 
ULK2, ATG13, ATG101, and the focal adhesion kinase 
family-interacting protein of 200 kDa (FIP200), is 
crucial for autophagy induction. Mammalian target of 
rapamycin complex 1 (mTORC1) binds to and inactivates 
ULK1 and ULK2. The dissociation of mTORC1 from 
the ULK complex leads to ULK1/2 activation and the 
subsequent phosphorylation of FIP200 and ATG13, 
which initiates phagophore formation [73]. The PI3K 
complex, which is essential for vesicle nucleation, is 
composed of class III PI3K, Beclin-1, ATG14L, p150, and 
several regulators including Ambra1, Bif-1, UV radiation 
resistance-associated gene (UVRAG), Bcl-2, Bcl-xL, 
and the Run domain protein Rubicon [74]. The LC3 and 
ATG12 ubiquitin-like protein conjugation systems are 
responsible for vesicle elongation. In the LC3 conjugation 
system, ATG4 cleaves pro-LC3 into cytosolic LC3-I, 
which successively binds to ATG7 and ATG3. LC3-I is 
processed by these two autophagy-related proteins and 
is then coupled to phosphatidylethanolamine (PE) to 
become a membrane-bound PE-conjugated LC3, LC3-II. 
In the ATG12 conjugation system, ATG12 successively 
binds to ATG7, ATG10, and ATG5 and finally conjugates 
with autophagy-related 16-like 1 (ATG16L1) to form 
the ATG16L1-ATG5-AGT12 complex [74, 75]. These 
two ubiquitination-like systems are closely connected. 
For example, the ATG16L1-ATG5-AGT12 complex 
is localized to the phagophore and potentially acts as a 
novel E3-like enzyme to determine the sites at which LC3 
conjugates with PE [76]. VMP1 is thought to function 
by recruiting Beclin-1 and other components in the class 
III PI3K complex to the phagophore, whereas ATG9 is 
thought to contribute to the delivery of membrane particles 
to the forming autophagosome [74]. The major autophagy 
cascades are depicted in Figure 2.
Autophagy is a wise strategy to protect cells against 
potential damage that is triggered by growth signal 
deficiency, nutrient deprivation (e.g., lack of glucose 
or amino acids), genotoxic stress (e.g., DNA damage), 
hypoxic stress, ER stress, and/or ROS accumulation [77].
The engagement of growth factor receptors 
activates the class I PI3K complex and a small GTPase, 
Ras, leading to the activation of the PI3K–PKD1–AKT 
pathway and the Ras-Raf-1–MEK1/2–ERK1/2 pathways, 
respectively. Both AKT and ERK1/2 phosphorylate and 
inhibit tuberous sclerosis complex (TSC) 1/2, thereby 
stabilizing Ras homolog enriched in brain (Rheb)-GTPase, 
which, in turn, activates mTORC1, causing the inhibition 
of autophagy [78]. In addition, high amino acid levels 
activate Rag GTPase to further activate the regulatory-
associated protein of mTOR (Raptor) in mTORC1, leading 
to the inhibition of autophagy [79]. Glucose deprivation 
causes an increased AMP:ATP ratio, which activates 
AMP-activated protein kinase (AMPK) directly or 
indirectly via liver kinase B1 (LKB1) [75]. Genotoxic 
stress induces p53 gene expression, and nuclear p53 
trans-activates a series of pro-autophagic genes, including 
sestrin1/2, TSC2, AMPK β1/β2, damage-regulated 
autophagy modulator (DRAM), DAPK, Bad, and Bax. In 
contrast to nuclear p53, cytoplasmic p53 plays an opposing 
role in the induction of autophagy by activating mTORC1 
[80]. ER stress also triggers autophagy in a Ca2+-dependent 
or -independent fashion. ER stress-induced Ca2+ release 
activates calcium/calmodulin kinase kinase β (CaMKKβ) 
and subsequently enhances AMPK activity. Furthermore, 
Ca2+ influx activates DAPK, which phosphorylates and 
activates Beclin-1, leading to phagophore formation. 
Moreover, ER stress can trigger autophagy in a Ca2+ 
-independent manner in which ER stress induces eukaryotic 
initiation factor 2α (eIF2α) phosphorylation and, in turn, 
up-regulates ATG12 expression [81]. Hypoxic stress 
triggers autophagy by activating TSC1 or by inhibiting 
Rheb via Bcl-2/adenovirus E1B 19-kDa-interacting protein 
3 (BNIP3) [82]. In addition, ROS acts as a potent inducer 
of autophagy by activating AMPK or by promoting ATG4 
activity to promote LC3 activation [81]. The induction and 
regulation of autophagy are diagrammed in Figure 3.
miRNAs regulate the major autophagy cascades
The ULK complex is situated at the beginning of 
the autophagy cascades. It was reported that miR-20a 
and miR-106b participate in the regulation of leucine 
deprivation-induced autophagy via the suppression of 
ULK1 expression in myoblasts [83].
Regarding class III PI3K, miR-338–5p was thought 
to silence the expression of its catalytic subunit (PIK3C3, 
or Vps34) and suppress autophagy, thereby enhancing 
colorectal cancer cell migration [84]. Beclin-1, a key 
component of the class III PI3K complex, is a direct 
target of miR-30a, miR-376b, and miR-216a. These 
three miRNAs negatively regulate Beclin-1 expression, 
causing decreased autophagic activity [85–87]. miR-374a 
and miR-630 were shown to suppress the expression of 
UVRAG, a regulator of the class III PI3K complex [88]. 
The regulatory effects of miRNAs on other effectors (i.e., 
Bcl-2 and Bcl-xL) of the class III PI3K complex have been 
discussed above.
miRNAs are also involved in the regulation of two 
conjugation systems. By targeting the LC3 beta isoform 
(LC3B), miR-204 impeded autophagy and suppressed 
the growth of renal clear cell carcinoma [89]. ATG4D, 
an ATG4 family member, is a direct target of miR-101, 
which was observed to act as a potent inhibitor of basal, 
etoposide- and rapamycin-induced autophagy [90]. 
Moreover, miR-376b was shown to silence the expression 
of the ATG4 family member ATG4C [86]. miR-17 directly 
interfered with the E1-like enzyme ATG7 and increased 
the sensitivity of cancer cells to chemotherapy drugs 
and to low-dose ionizing radiation treatment in human 
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glioblastoma cells [91]. Similarly, miR-375 reduced ATG7 
expression by directly targeting and inhibiting autophagy, 
leading to a reduction in the viability of hepatocellular 
carcinoma cells under hypoxic conditions [92]. ATG12 is 
a target of miR-23b. In pancreatic cancer cells, decreased 
miR-23b expression increased ATG12 expression and 
autophagic activity, thereby promoting radio-resistance 
[93]. Additionally, miR-630 was thought to act as another 
direct suppressor of ATG12 [88]. miR-519a was observed 
to target the E2-like enzyme ATG10; miR-106b and miR-
519a target ATG16L1; and miR-181a, miR-374a, and 
miR-30a target ATG5 [88, 94, 95].
VMP1, a critical transmembrane protein for 
phagophore formation, is a direct and functional 
downstream target of miR-210 that is induced by 
hypoxia and that augments the metastatic potential of 
hepatocellular carcinoma cells (Figure 2) [96].
miRNAs are involved in the induction and regulation 
of autophagy
Starvation, genotoxic stress, hypoxic stress, ER 
stress, and ROS activate a series of signaling pathways 
to initiate or regulate autophagy cascades. AMPK-
mTORC1 serves as the center of autophagy regulation by 
Figure 2: miRNAs regulate the major cascades of autophagy. Autophagy includes at least six successive events: induction, 
vesicle nucleation (or phagophore formation), vesicle elongation and autophagosome formation, ATG protein and lipid retrieval, fusion of 
the autophagosome to an lysosome/endosome and autolysosome formation, and autolysosome cargo degradation. The ULK complex, which 
is composed of ULK1/2, ATG13, FIP200, and ATG101, is activated by the inhibition of mTORC1 and initiates the autophagy program. The 
class III PI3K complex, which is composed of Beclin-1, class III PI3K (i.e., Vps34), p150 (i.e., Vps15), ATG14L, and certain regulatory 
factors, is essential for vesicle nucleation. Two ubiquitin-like protein conjugation systems form two important complexes (the LC3-II-
PE complex and the ATG5-ATG12-ATG16L1 complex) that are critical for vesicle elongation. The transmembrane proteins VMP1 and 
ATG9 also play a role in nascent autophagosome formation. The major miRNAs involved in the regulation of key members of autophagy 
cascades are shown in the diagram in dark blue. mTORC1, mammalian target of rapamycin complex 1; ULK, UNC-51-like kinase; ATG, 
autophagy-related gene; FIP200, focal adhesion kinase family-interacting protein of 200 kDa; UVRAG, UV radiation resistance-associated 
gene; Rubicon, RUN domain protein as Beclin-1 interacting and cysteine-rich containing; PE, phosphatidylethanolamine; VMP1, vacuole 
membrane protein 1; PI3K, phosphatidylinositol-3 kinase. Pro-LC3, primary translation product of LC3; LC3-I, cytosolic form of LC3 that 
is cleaved from Pro-LC3 by ATG4; LC3-II, lipidated form of LC3 that is conjugated to PE. See the text for details.
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integrating numerous stimuli and pathways into a signal 
for the ULK complex, the starting point of autophagy. 
Several miRNAs have been reported to regulate AMPK-
mTORC1. miR-148b was reported to target AMPKα1 
to inhibit cell proliferation and invasion and to enhance 
cancer cell chemosensitivity [97]. miR-26b direct targeted 
and repressed TGF-β-activated kinase 1 (TAK1, a classic 
AMPK and NF-κB activator) and other factors to enhance 
the chemosensitivity of hepatocellular carcinoma cells 
[98]. Moreover, miR-99a was observed to target mTOR 
and to suppress the tumorigenicity of lung cancer cells 
[99]. miR-199a-3p regulated mTOR and c-Met to reduce 
cell invasion and to increase the sensitivity of human 
hepatocarcinoma cells to doxorubicin [100].
As for class I PI3K, recent studies showed that the 
PI3K regulatory subunit p85α (i.e., PIK3R1) serves as a 
Figure 3: Induction and regulation of autophagy by miRNAs. Growth signals, energy status (the abundance of glucose and amino 
acids), genotoxic stress, hypoxic stress, ER stress, and ROS elicit a series of signaling pathways that initiate or repress autophagy cascades. 
AMPK-mTORC1 lies at the heart of regulation of autophagy by integrating numerous stimuli and pathways into a signal for the starting 
point of autophagy, the ULK complex. In addition, ER stress and ROS regulate autophagy independently of the AMPK-mTORC1 pathway. 
The major miRNAs involved in autophagy regulation are shown in the diagram in dark blue. PDK1, 3-phosphoinositide-dependent protein 
kinase-1; TSC, tuberous sclerosis complex; Rheb, Ras homolog enriched in brain (a GTPase); REDD1, regulated in development and DNA 
damage responses 1; BNIP3, Bcl-2/adenovirus E1B 19-kDa-interacting protein 3; mLST8, mammalian lethal with Sec13 protein 8, also 
referred to as GβL; mTOR, mammalian target of rapamycin; Raptor, regulatory-associated protein of mTOR; MEK, mitogen-activated 
protein kinase kinase; Rag, a GTPase family member; AMPK, AMP-activated protein kinase; TAK1, TGF-β-activated kinase 1; LKB1, 
liver kinase B1; DRAM, damage-regulated autophagy modulator; DAPK, death-associated protein kinase; CAMKKβ, calcium/calmodulin 
kinase kinase β; eIF2α, eukaryotic initiation factor 2α. See the text for details.
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direct target of miR-503. The ectopic expression of miR-
503 suppressed non-small-cell lung cancer (NSCLC) cell 
proliferation and metastasis-related characteristics both 
in vitro and in vivo [101]. miR-193a-5p inactivated the 
AKT/mTOR signaling pathway by directly targeting the 
class I PI3K regulatory subunit p55γ (i.e., PIK3R3) and 
mTOR, which suppressed NSCLC metastasis [102]. miR-
148b was reported to reduce breast cancer malignancy by 
coordinating a novel pathway involving the PI3K catalytic 
subunit p110α (i.e., PIK3CA) [103]. Additionally, the 
PI3K catalytic subunit p110δ (i.e., PIK3CD) was directly 
regulated by miR-30b or miR-663 in human colorectal 
cancer and glioblastoma cells, respectively [104, 105]. 
Phosphatase and tensin homolog (PTEN), a negative 
regulator of the PI3K signaling pathway, was demonstrated 
as a hot target of a number of miRNAs, including miR-21, 
miR-214, miR-216a, miR-217, miR-26a, and miR-18a, 
which are involved in the regulation of several cancer 
types [106–110]. miR-375 was reported to suppress the 
expression of 3-phosphoinositide-dependent protein 
kinase-1 (PDK1), another effector in the PI3K signaling 
pathway that is often down-regulated in gastric carcinoma 
cases and that is involved in the regulation of cell survival 
[111]. miR-9500 was shown to regulate the proliferation 
and migration of human lung cancer cells by targeting 
AKT1 [112]. In addition, miR-302–367 was observed to 
be involved in the translational inhibition of AKT1 [113]. 
Rheb, a negative regulator of autophagy upstream of 
mTORC1, was silenced by miR-155 via binding to its 3′-
UTR, leading to the promotion of autophagy [114, 115]. 
The major members of the Ras-Raf-1-MEK1/2-ERK1/2 
signaling pathway are also under the control of miRNAs. 
Dozens of miRNAs such as miR-21 and miR-216b [116, 
117] were reported to regulate Ras expression and to play 
a role in tumor suppression107, 108. miR-195 was shown to 
target Raf-1 [118], miR-1826 and miR-34a to MEK1 [119, 
120], and miR-483–5p to ERK1 [121].
Hypoxia increases the expression of miR-210, which 
suppresses BNIP3 expression and maintains cell survival 
under hypoxic conditions [122]. miR-495 directly suppresses 
the expression of a downstream component of BNIP3, 
regulated in development and DNA damage responses 1 
(REDD1) and enhances breast cancer stem cell proliferation 
under hypoxic conditions via a post-transcriptional 
mechanism [123]. Similarly, other modulators (e.g., ATG4, 
LC3, DAPK, Beclin-1, ATG12, and Bax) of the ER stress-, 
ROS-, and genotoxic stress-induced autophagy pathways are 
regulated by miRNAs; most of these modulators have been 
described above (Figure 3).
MicroRNAs and necroptosis
Necrosis was traditionally thought to be an accidental 
and unregulated type of cell death. However, emerging 
evidence has shown that necrosis can be induced and 
regulated in a similar manner to apoptosis. Regulated 
necrosis is termed “programmed necrosis” or “necroptosis” 
to distinguish this process from necrosis induced by 
physical trauma [124]. Necroptosis can be induced by 
the engagement of the TNF receptor superfamily, T-cell 
receptor (TCR), interferon receptors (IFNRs), Toll-like 
receptors (TLRs), cellular metabolic and genotoxic stresses, 
and a number of anti-cancer agents [125]. Necroptosis can 
be pharmacologically inhibited using certain chemical 
compounds such as necrostatin-1 [126]. The formation of 
the “necrosome” by receptor-interacting protein kinase 1 
(RIP1, also known as RIPK1) and RIP3 is the most critical 
event in necroptosis. Multiple stimuli and pathways that 
induce necroptosis ultimately converge at the RIP1-RIP3 
necrosome. In TNF-α-induced necroptosis, the engagement 
of the TNF receptor recruits a series of proteins including 
TNFR1-associated death domain protein (TRADD), RIP1, 
TNF receptor-associated factor 2 (TRAF2), deubiquitinase 
cylindromatosis (CYLD), and cIAP1/2 to form a large 
complex termed Complex I. In this complex, cIAP1 
and cIAP2 ubiquitinate RIP1 and prevent its entrance 
into Complex II a (composed of caspase-8, FADD, and 
RIP1) and Complex II b [composed of caspase-8, FADD, 
RIP1, RIP3, and mixed lineage kinase domain-like 
(MLKL)] [127], thus restricting subsequent apoptosis or 
necroptosis. Moreover, the poly-ubiquitination of RIP1 
promotes NF-κB activation and cell survival. In contrast, 
CYLD is a deubiquitinating enzyme that is responsible 
for the removal of ubiquitin chains from RIP1 and that 
promotes the formation of ComplexIIa. Subsequently, 
caspase-8 cleaves RIP1 and RIP3, thus preventing their 
trans-phosphorylation and their phosphorylation of 
downstream necroptotic factors. However, if caspase-8 is 
inactivated by pharmacological inhibitors (e.g., zVAD), 
endogenous inhibitors (e.g., c-FLIP
S
), or genetic caspase-8 
or FADD inhibition/deletion, it loses its capacity to cleave 
RIP1 and RIP3, leading to the phosphorylation of these 
two kinases and the formation of the filamentous-like 
RIP1-RIP3 complex, or the necrosome. The RIP1-RIP3 
necrosome subsequently recruits and activates MLKL 
and phosphoglycerate mutase 5 (PGAM5), two critical 
downstream targets of RIP3 [128, 129]. During TNF-
induced necroptosis, MLKL is phosphorylated by RIP3, 
forms a homotrimer via its amino-terminal coiled-coil 
domain, and translocates to the plasma membrane, and these 
events lead to necrotic plasma membrane permeabilization 
[130]. Upon necrosis induction, PGAM5S (a short form of 
PGAM5) recruits the mitochondrial fission factor dynamin-
related protein 1 (Drp1) and activates its GTPase activity by 
dephosphorylating Drp1 at serine 637. Drp1 activation leads 
to mitochondrial fission, which is an early and necessary 
step for necrosis execution (shown in Figure 4) [131].
At present, few studies have reported on how 
miRNAs regulate necroptotic cell death. miR-155 has been 
reported to prevent necroptosis in human cardiomyocyte 
progenitor cells by directly targeting RIP1 [132]. miR-499 
can suppress the calcineurin-mediated dephosphorylation 
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Figure 4: miRNAs regulate necroptosis. Necroptosis is triggered by TNF receptor superfamily members, TLRs, IFNRs, TCR, 
cellular metabolic and genotoxic stresses, and anticancer drugs. In TNF-α-induced necroptosis, the engagement of TNFR1 recruits 
Complex I (composed of TRADD, RIP1, TRAF2, CYLD, and cIAP1/2). In this complex, cIAP1 and cIAP2 ubiquitinate RIP1, whereas 
CYLD deubiquitinates RIP1. Polyubiquitinated RIP1 promotes NF-κB activation and prevents the formation of Complex II a (composed 
of caspase-8, FADD, RIP1) and Complex II b (composed of caspase-8, FADD, RIP1, RIP3, and MLKL), thus promoting cell survival and 
inhibiting apoptosis and necroptosis. RIP1 deubiquitination enables Complex II a formation, but whether the cell undergoes necroptosis is 
dependent on caspase-8 activity. Activated caspase-8 cleaves RIP1 and RIP3 and blocks necroptosis. However, if caspase-8 is inactivated 
by a pharmacological inhibitor (e.g., zVAD), an endogenous inhibitor (e.g., c-FLIP
S
) or genetic caspase-8 or FADD inhibition/deletion, it 
loses the capacity to cleave RIP1 and RIP3, leading to the trans-phosphorylation of these two kinases and the formation of a filamentous-
like complex termed the necrosome. The RIP1-RIP3 necrosome subsequently recruits and activates MLKL and PGAM5. MLKL is 
phosphorylated by RIP3 and then forms a homotrimer that translocates to the plasma membrane, and this event leads to necrotic plasma 
membrane permeabilization. Upon necrosis induction, PGAM5S recruits and activates Drp1, which leads to mitochondrial fission, which 
is an early and necessary step for necrosis execution. The miRNAs involved in the regulation of key components of the necroptotic 
pathway are shown in the diagram in dark blue. TLRs, Toll-like receptors; TCR, T-cell receptor; IFNRs, interferon receptors; TNFR1, 
TNF-α receptor 1; TRADD, TNFR1-associated death domain protein; TRAF2, TNF receptor-associated factor 2; CYLD, cylindromatosis; 
cIAP1/2, cellular inhibitor of apoptosis 1/2; RIP1, receptor-interacting protein kinase 1, also referred to as RIPK1; IKK, IκB kinase; 
c-FLIP
S
, cellular FLICE-like inhibitory protein, short form. PGAM5, phosphoglycerate mutase 5; MLKL, mixed lineage kinase domain-
like; Drp1, dynamin-related protein 1.
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of Drp1, thus inhibiting Drp1 accumulation in mitochondria 
and Drp1-mediated mitochondrial fission [133]. CLYD, the 
key deubiquitinating enzyme in the apoptosis/necroptosis 
pathway, was directly targeted by miR-181b-1 and miR-
19, resulting in the hyperactivation of the NF-κB signaling 
pathway and in a high inflammatory status in cancer cells; 
these events contribute to tumor progression [134, 135]. 
In addition, miR-874 was reported to enhance necroptosis 
by targeting caspase-8, which acts as a key modulator of 
the transition between apoptosis and necroptosis [42]. To 
date, no report has demonstrated how miRNAs regulate 
other key necroptotic factors, including RIP3, MLKL, and 
PGAM5 (Figure 4).
MicroRNAs regulate the crosstalk between 
apoptosis, autophagy, and necroptosis
The molecular mechanisms underlying the interaction 
between apoptosis, autophagy and necroptosis involve 
several key nodes including Bcl-2, Beclin-1, ATG3, 
cFLIP, cIAPs, ATG5, Bcl-xL, JNK1, p53, p62, caspase-3, 
caspase-8, and DAPK. For example, under nutrient-rich 
conditions in which autophagy is unnecessary, Bcl-2 and 
Bcl-xL bind to and inhibit the autophagy inducer Beclin-1 
[136]. However, when cells are subjected to starvation, 
the binding activity of Bcl-2 and Bcl-xL is weakened 
by JNK1-mediated Bcl-2 phosphorylation to initiate 
autophagy, which promotes cell survival [137]. Similarly, the 
pro-apoptotic factor DAPK phosphorylates Beclin-1, 
promoting its dissociation from Bcl-2 and activating 
autophagy [138]. Caspase-3, -7, and -8 cleave two crucial 
components of the autophagy-inducing complex, Beclin-1 
and Class III PI3K. The cleaved fragments of Beclin-1 
lose their capacity to induce autophagy. Notably, the 
C-terminal fragment of Beclin-1 predominantly localizes 
to mitochondria and sensitizes cells to apoptosis [139]. 
Similarly, the cleavage of the autophagic protein ATG5 by the 
pro-apoptotic factor calpain can also facilitate the conversion 
from autophagy to apoptosis. Truncated ATG5 translocates 
from the cytosol to mitochondria and associates with the 
anti-apoptotic molecule Bcl-xL, inducing cytochrome 
c release and caspase activation [140, 141]. p62, a factor that 
is responsible for packaging misfolded/damaged proteins 
into the autophagosome, has been shown to be involved in 
apoptosis induction by targeting proteasomal degradation 
[142]. The tumor suppressor p53 plays a vital role in the 
regulation of apoptosis cascades. However, accumulating 
evidence supports the additional function of p53 in the 
regulation of autophagy via different pathways depending 
on its subcellular localization. On one hand, nuclear p53 
functions as a transcription factor to trans-activate several 
pro-autophagic genes (e.g., DRAM) [143]; on the other 
hand, cytoplasmic p53 tends to repress autophagy [80].
cFLIP, a negative regulator of caspase-8, binds 
to ATG3 and blocks its conjugation to LC3, thereby 
attenuating autophagy [144]. In addition, cFLIP mediates 
Figure 5: MiRNAs regulate the crosstalk between apoptosis, autophagy, and necroptosis. Accumulating studies have shown 
that a close interaction between apoptosis, autophagy, and necroptosis. Some proteins that are conventionally thought to participate in 
apoptosis (blue) may play novel roles in autophagy or necroptosis. Alternatively, some autophagy modulators (yellow) may play a role in 
other modes of programmed cell death. The major miRNAs involved in the regulation of the crosstalk between apoptosis, autophagy, and 
necroptosis are shown in the diagram in dark blue. See the text for details.
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the transition between apoptosis and necroptosis. In the 
absence of cFLIP, cells undergo apoptosis rather than 
necroptosis due to the high activity of caspase-8. A long 
isoform of cFLIP (cFLIPL) binds to caspase-8 to inhibit 
caspase-8-mediated apoptosis cascades. However, this 
cFLIPL-caspase-8 heterodimer retains the ability to 
cleave RIP1, which blocks RIP1–RIP3 formation and 
necroptosis [145]. In contrast, a short isoform of cFLIP 
(cFLIP
S
) is able to bind to caspase-8 to inhibit apoptosis, 
but the cFLIP
S
-caspase-8 heterodimer lacks the capacity 
to cleave RIP1, leading to the formation of the RIP1–
RIP3 complex and the initiation of necroptosis. This 
reveals a triple role of FLIP, which controls apoptosis, 
autophagy, and necroptosis at the same time. The E3 
ligases cIAP1 and cIAP2 mediate RIP1 ubiquitination, 
which not only promotes NF-κB activation but also 
inhibits the binding of RIP1 to Complex II, leading to 
the suppression of apoptosis and necroptosis [146]. The 
miRNAs involved in the regulation of this crosstalk are 
depicted in Figure 5.
Perspectives
In this review, we have summarized and 
discussed how miRNAs regulate apoptosis, autophagy, 
and necroptosis and have listed their roles in cancer 
progression. However, a few important questions remain 
to be answered.
(1) To date, limited studies have examined how 
miRNAs are involved in the regulation of necroptosis. 
No study has reported on whether and how certain key 
necroptotic pathway components such as RIP3, MLKL, 
and PGAM are influenced by miRNAs.
(2) One miRNA may target more than one 
component of a death pathway and even more than one 
death pathway. For example, miR-30a targets Beclin-1, 
ATG5, and p53; miR-155 regulates FADD, caspase-3, 
Rheb, and RIPK1. It is necessary to understand the 
crosstalk between these different regulatory activities and 
the strength of each regulatory effect.
(3) Because targeting cell death pathways represents 
a promising strategy to treat cancer, the potential clinical 
applications of miRNAs warrant investigation.
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